Comparing two blood-transfusion strategies for liver patients before procedures
Part of Digestive system clinical trials.
This trial tests whether using a slightly different target on a blood-clotting test (ROTEM) can reduce the need for blood transfusions in people with liver disease who need a procedure. If you have cirrhosis or ACLF with severe clotting problems, this study may help your doctors decide how much blood product to give you before the procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cirrhosis or acute-on-chronic liver failure (ACLF).
- You are scheduled for an invasive procedure (like a biopsy or drainage).
- Your clotting is very weak: either high INR (over 2.0), very low platelets (under 30,000), or low fibrinogen (under 100).
- You are not currently bleeding and haven't had bleeding in the last 48 hours.
- You have not taken blood thinners (like aspirin or warfarin) in the past 7 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a treatment called therapeutic plasma exchange (a process that filters your blood) can help improve the function of other organs in people with severe liver failure. It aims to see if this treatment leads to better outcomes and to find markers that predict who will benefit.
This trial compares two tests (ROTEM and TEG) that help doctors decide which blood products to give to cirrhosis patients with active stomach or intestinal bleeding that is not from varices. The goal is to find which test works better.
This trial is testing if a special blood test called ROTEM can help doctors predict the risk of bleeding after high-risk procedures in people with cirrhosis. It aims to improve safety and guide treatment decisions.
This study compares a special blood test (thrombelastometry) to standard tests to decide when to give blood products before invasive procedures in people with advanced liver cirrhosis. The goal is to see which method leads to better use of blood products and fewer complications.
This trial compares how well an artificial intelligence (AI) tool interprets ROTEM blood-clotting tests compared to human experts. The results could help doctors make faster and more accurate decisions about bleeding or clotting problems.
This Phase 4 study looks at how clotting measurements relate to bleeding risk in people with liver cirrhosis who need a planned liver procedure. The study may help doctors understand what coagulation results mean when doing these procedures safely.
Hear when a new Acute-On-Chronic Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.